ARTELO BIOSCIENCES, INC.

ARTL
NasdaqPharmaceutical PreparationsCA

-5.3%

since IPO

IPO Price

$3.77

Current Price

$3.57

Return

-5.3%

Market Cap

$3.3M

IPO Date

Apr 16, 2026

Lockup End

Oct 13, 2026

Lockup Status

167days until lockup expires

Price Performance

Stock price vs IPO price over time (sample data)

Stock Price
IPO Price
Lockup End

Performance Summary

First Day
N/A
1 Month
N/A
3 Months
N/A
6 Months
N/A
1 Year
N/A
Since IPO
-5.3%

ARTELO BIOSCIENCES, INC. (ARTL) — IPO Analysis

By Kian O Connor | Updated 4/29/2026

Company Overview

ARTELO BIOSCIENCES, INC. (ticker: ARTL) specializes in specialty pharmaceutical formulations while maintaining strategic capabilities in geriatric-specific medications, positioning itself within the Pharmaceutical Preparations sector through supply chain reliability and innovative technology platform. The company has developed its operations around quality assurance systems, creating market differentiation through specialized expertise and performance-based contracts that supports sustainable growth and customer relationship development. The company completed its public offering on 2026-04-16, accessing capital markets during regulatory landscape changes within the Pharmaceutical Preparations landscape. The IPO timing reflected the company's strategic positioning and growth trajectory, with market reception emphasizing management's execution capabilities and the company's approach to specialty pharmaceutical formulations as key value creation drivers in an evolving competitive environment. Post-IPO trading performance has demonstrated mixed market reception as investors assess business model adaptation and strategic positioning within industry trends. Market assessment focuses on the company's supply chain reliability and strategic emphasis on geriatric-specific medications as indicators of long-term competitive positioning within the Pharmaceutical Preparations sector, with investors evaluating operational execution and market opportunity capture relative to industry development trends. The lockup period expires December 05, 2026, providing market insights into management and early investor confidence in strategic direction and competitive positioning. Given the company's focus on specialty pharmaceutical formulations and emphasis on quality assurance systems, insider trading decisions will likely reflect assessments of execution progress, competitive dynamics, and growth opportunity realization within the evolving Pharmaceutical Preparations market landscape.

Performance Overview

Since going public at $3.77 per share on Apr 16, 2026, ARTELO BIOSCIENCES, INC. shares have declined 5.3%, disappointing investors who participated in the IPO. The stock currently trades at $3.57, giving the company a market capitalization of $3.3M.

Lockup Expiration

The lockup period for ARTELO BIOSCIENCES, INC. insiders is set to expire on Oct 13, 2026, which is 167 days from now. When the lockup expires, insiders and early investors who received shares before the IPO will be free to sell their holdings on the open market. This can create significant selling pressure and is closely watched by traders and institutional investors alike.

Industry Context

ARTELO BIOSCIENCES, INC. operates in the Pharmaceutical Preparations sector, which has seen varied IPO activity in recent years. The company is headquartered in CA and is classified under SIC code 2834. Understanding the competitive landscape and sector dynamics is essential for evaluating the long-term prospects of any newly public company in this space. Investors should consider broader market conditions, sector-specific trends, and company fundamentals when assessing ARTL as an investment.

Trading History

ARTELO BIOSCIENCES, INC. is actively trading in the public markets with a current share price of $3.57. The company went public at $3.77 per share, representing a decline of 5.3% from the initial offering price. With a current market capitalization of $3.3M, ARTELO BIOSCIENCES, INC. continues to establish its presence as a publicly traded entity in the Pharmaceutical Preparations.

Important Disclaimer

This analysis of ARTELO BIOSCIENCES, INC. (ARTL) is provided for informational purposes only and should not be construed as investment advice. All data is sourced from SEC EDGAR filings and public market feeds. Past performance is not indicative of future results. Investors should conduct their own due diligence and consult with a qualified financial advisor before making investment decisions. IPOLockup.io is an independent research platform with no financial interest in any of the companies covered.

Insider Selling Activity

Estimated insider trading activity around lockup expiry period (sample data)

3
Pre-Expiry Average
Minimal
84
Expiry Day
Very High
58
Post-Expiry (30d)
High

Activity Heatmap

60 days before/after lockup expiry
Intensity Scale:
Minimal
Low
Moderate
High
Very High
Lockup Expiry

About This Data

This heatmap shows estimated insider selling activity based on typical patterns around lockup expiry periods. Actual data would be derived from SEC Form 4 filings. Higher intensity indicates more insider transactions, which may correlate with increased selling pressure and potential stock price volatility.

Related IPOs

TickerCompanyIndustryIPO DateIPO PriceCurrentReturn
SWRDStewards, Inc.Short-Term Business Credit InstitutionsApr 28, 2026$2.71$2.60-4.1%
COAGHemab Therapeutics Holdings, Inc.Biological Products, (No Diagnostic Substances)Apr 28, 2026N/AN/AN/A
REARare Earths Americas, Inc.Metal MiningApr 28, 2026N/AN/AN/A
QLEPQuantum Leap Acquisition CorpBlank ChecksApr 28, 2026N/AN/AN/A
ASFHASIAFIN HOLDINGS CORP.Services-Business Services, NECApr 28, 2026$0.51$0.51+0.0%
GMRSGMR Solutions Inc.Transportation ServicesApr 28, 2026N/AN/AN/A
IACQIrenic Acquisition Corp.Blank ChecksApr 28, 2026N/AN/AN/A
CXIIChurchill Capital Corp XIIBlank ChecksApr 28, 2026N/AN/AN/A

Related IPO Analysis

KO
By • Founder & Data Analyst